The information highlighted (if any) are the most recent updates for this brand.
This product as monotherapy is indicated for patients with metastatic colorectal cancer (mCRC) who have previously received fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy, and those who have previously received or are not suitable for receiving anti-vascular endothelial growth factor (VEGF) therapy or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild-type).